Hepatoblastoma is a form of liver cancer affecting children and for which the current treatment option available is surgical resection followed by chemotherapy based on cisplatin or doxorubicin. Its prognosis is still poor, and the recurrence rate is high. Neddylation is a biological process that has been well studied for its role in cancer biology; Spanish researchers have hypothesized that neddylation may play a significant role in the development and progression of hepatoblastoma.

At the recent 2025 congress of the European Crohn’s and Colitis Organisation, researchers from Helixon Therapeutics presented the discovery and preclinical characterization of HXN-1002, a bispecific antibody simultaneously targeting both α4β7 and TL1A that is being investigated as a potential treatment for inflammatory bowel disease.

Anterior gradient 2 (AGR2) is a protein located in the endoplasmic reticulum involved in protein folding and when stressed, it is secreted into the extracellular space and it attracts monocytes, activates fibroblasts and disrupts the epithelial integrity. The relationship between the expression of AGR2 in tissues from patients with inflammatory bowel disease (IBD) was investigated, as well as the efficacy of an anti-AGR2 antibody in murine models of colon inflammation and fibrosis.

Thetis Pharmaceuticals LLC has presented preclinical data on their BLT1 receptor agonist TP-317 as an approach for treating inflammatory bowel disease. BLT1 activation promotes immune homeostasis and repair; oral therapy with TP-317 was investigated in two preclinical models of colitis and ileitis.

In autoimmune diseases such as inflammatory bowel disease (IBD), the function of regulatory CD8 T cells (CD8 Treg) is compromised, in part due to the expression of inhibitory KIR receptors (KIR2DL1/2/3) and insufficient inducible T-cell co-stimulator (ICOS) signaling. Mozart Therapeutics Inc. has discovered MTX-201, a new bispecific antibody targeting inhibitory KIR and ICOS that are co-expressed by CD8 Tregs.

Bambusa Therapeutics Inc. has completed an oversubscribed series A financing of approximately $90 million to support its lead programs through phase I trials and advance its pipeline of long-acting bispecific antibodies for immunological and inflammatory disorders.

Stimulating the body’s immune defenses against a tumor can reduce or eliminate it. However, in cancer immunotherapy, when immune checkpoint inhibitors unleash the immune system, severe autoimmunity can result. A hematological technique, extracorporeal photopheresis (ECP), could offer a solution. It reduces the therapy-induced inflammation without altering antitumor immunity. According to scientists at the Universities of Basel and Freiburg, the key lies in adiponectin, a hormone produced by fatty tissue.

Shanghai Microport Medbot (Group) Co. Ltd. won China National Medical Products Administration approval of its self-developed Toumai single-arm and single-port laparoscopic surgical robot.